Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that two injections of platelet-rich plasma were safe but no more effective than placebo in treating mild to moderate erectile dysfunction.

This study found that isolated human scalp hair follicles express PGE2 genes and EP2 protein, suggesting PGE2 may play a crucial role in regulating hair growth.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

This review summarizes the roles of PDGF and its receptors in cell development and wound healing, reporting no new research findings; the authors emphasize PDGF's diverse biological functions.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This study found that dutasteride may help prevent enteric neuronal damage in an animal model of Parkinson's disease, highlighting its potential for drug repurposing to address neuroinflammation.

This study used high-resolution ultrasound to investigate the pathophysiology of persistent erectile dysfunction in young men who used the drug finasteride, observing differences in erectile tissue homogeneity compared to control subjects without finasteride exposure.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that the 5α-steroid metabolite profile in men with inherited 5α-reductase deficiency is similar to those taking the drug finasteride, suggesting the gene affects multiple steroid substrates.

This study found that PRP injections are safe and may slightly reduce penile curvature and improve PDQ scores in men with stable-phase Peyronie's Disease, but the changes are not significant enough to predict long-term effects.

This study identified CXXC5 as a key mediator of hair loss induced by PGD2 and DHT via suppression of the Wnt/β-catenin pathway, with implications for potential therapeutic targets.

This study suggests that PDCD4 regulates keratinocyte proliferation and contact inhibition, playing a role in epidermal homeostasis and wound healing.

In this study, androgen was found to increase VEGF expression, but not VEGFR-2, in rat corpus cavernous, with DHT likely playing a key role.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study observed that equine epididymis mainly expresses the type 1 isoform of 5α-reductase and effectively converts progesterone and testosterone to DHP and DHT, while finasteride and dutasteride inhibited this activity.

This study found that the peptides RMYYY and VMYMI displayed stronger binding energy and more frequent interactions with HPGDS compared to the native inhibitor, suggesting potential as future therapeutic drugs.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

This review outlines how peptidyl arginine deiminases (PADIs) and protein citrullination are involved in hair follicle regeneration and inflammatory alopecia, but presents no new clinical findings.

This study demonstrated that α-phellandrene promotes dermal papilla cell proliferation through a cAMP-mediated pathway and upregulates VEGF expression, suggesting its potential use in hair loss prevention.

This abstract reviews the role of finasteride and potential dual 5alpha-reductase inhibitors in treating benign prostatic hyperplasia, suggesting that dual inhibitors may offer greater DHT suppression and therapeutic advantages, while emphasizing the need for clinical evaluation.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.

This study evaluates finasteride's safety and efficacy for treating male chronic pelvic pain syndrome, but the abstract does not report any results.

This study used Density Functional Theory to calculate finasteride's molecular properties, finding the GGA/PW91 method aligns well with experimental data and identifying key reactive sites for chemical interactions.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.